Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc. is an American healthcare company, founded in 1998 and based in San Diego, California. The company operates as a biopharma technology platform company serving clients in the United States, Switzerland, and internationally. The organisation combines technology with established and emerging healthcare treatments, with the goal of developing innovative solutions that impact patient experience and patient outcomes. Halozyme Therapeutics, Inc. is traded on the NASDAQ GS with the ticker HALO. It has been trading as a public company since 2004. The HALO share price showed a 52-week low of $12.71 and a 52-week high of, $29.77, as of October 2020. Halozyme does not currently pay a dividend to stockholders and has no plans to do so in the foreseeable future. The company has developed a proprietary enzyme that forms the basis of its patented ENHANZE® drug delivery technology. As of October 2020, the organisation has five products on the market that have received regulatory approvals — either within the United States or across global markets — that utilise the enzyme. If you are interested in adding a new healthcare stock to your portfolio, you can invest in HALO stock today, or add it to your watchlist to monitor price movements.